179 related articles for article (PubMed ID: 28458384)
1. Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma.
Yano H; Shinoda J; Iwama T
Neurol Med Chir (Tokyo); 2017 Jul; 57(7):312-320. PubMed ID: 28458384
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between primary low-grade and high-grade glioma with
Falk Delgado A; Falk Delgado A
Br J Radiol; 2018 Feb; 91(1082):20170426. PubMed ID: 29206062
[TBL] [Abstract][Full Text] [Related]
3. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
[TBL] [Abstract][Full Text] [Related]
4. A False-Negative Case of Primary Central Nervous System Lymphoma on 11C-Methionine PET and Intense 18F-FDG Uptake.
García-Garzon JR; Villasboas-Rosciolesi D; Baquero M; Bassa P; Soler M; Riera E
Clin Nucl Med; 2016 Aug; 41(8):664-5. PubMed ID: 27187734
[TBL] [Abstract][Full Text] [Related]
5. Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
Bénard F; Romsa J; Hustinx R
Semin Nucl Med; 2003 Apr; 33(2):148-62. PubMed ID: 12756647
[TBL] [Abstract][Full Text] [Related]
6. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
7. Primary Central Nervous System Natural Killer Cell Lymphoma in a Chinese Woman with Atypical (11)C-Choline Positron Emission Tomography and Magnetic Resonance Spectrometry Findings.
Li LF; Taw BB; Pu JK; Hwang GY; Lui WM; Leung GK
World Neurosurg; 2015 Oct; 84(4):1176.e5-9. PubMed ID: 26142813
[TBL] [Abstract][Full Text] [Related]
8. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.
Watanabe A; Muragaki Y; Maruyama T; Shinoda J; Okada Y
J Neurooncol; 2016 Feb; 126(3):577-83. PubMed ID: 26612734
[TBL] [Abstract][Full Text] [Related]
10. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
12. Applications of positron emission tomography in neuro-oncology: a clinical approach.
Demetriades AK; Almeida AC; Bhangoo RS; Barrington SF
Surgeon; 2014 Jun; 12(3):148-57. PubMed ID: 24629841
[TBL] [Abstract][Full Text] [Related]
13. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
[TBL] [Abstract][Full Text] [Related]
14. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
Gumprecht H; Grosu AL; Souvatsoglou M; Dzewas B; Weber WA; Lumenta CB
Zentralbl Neurochir; 2007 Feb; 68(1):19-23. PubMed ID: 17487804
[TBL] [Abstract][Full Text] [Related]
15. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography.
Galldiks N; Kracht LW; Dunkl V; Ullrich RT; Vollmar S; Jacobs AH; Fink GR; Schroeter M
Mol Imaging; 2011 Dec; 10(6):453-9. PubMed ID: 22201536
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.
Pirotte B; Goldman S; Massager N; David P; Wikler D; Vandesteene A; Salmon I; Brotchi J; Levivier M
J Nucl Med; 2004 Aug; 45(8):1293-8. PubMed ID: 15299051
[TBL] [Abstract][Full Text] [Related]
17. PET imaging in glioma: techniques and current evidence.
Mansoor NM; Thust S; Militano V; Fraioli F
Nucl Med Commun; 2018 Dec; 39(12):1064-1080. PubMed ID: 30303860
[TBL] [Abstract][Full Text] [Related]
18. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.
Braunstein S; Raleigh D; Bindra R; Mueller S; Haas-Kogan D
J Neurooncol; 2017 Sep; 134(3):541-549. PubMed ID: 28357536
[TBL] [Abstract][Full Text] [Related]
19. Role of [(11)C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours.
Cicuendez M; Lorenzo-Bosquet C; Cuberas-Borrós G; Martinez-Ricarte F; Cordero E; Martinez-Saez E; Castell-Conesa J; Sahuquillo J
Clin Neurol Neurosurg; 2015 Dec; 139():328-33. PubMed ID: 26588352
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma.
Nariai T; Tanaka Y; Wakimoto H; Aoyagi M; Tamaki M; Ishiwata K; Senda M; Ishii K; Hirakawa K; Ohno K
J Neurosurg; 2005 Sep; 103(3):498-507. PubMed ID: 16235683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
